Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SNTA > SEC Filings for SNTA > Form 8-K on 20-Mar-2014All Recent SEC Filings

Show all filings for SYNTA PHARMACEUTICALS CORP

Form 8-K for SYNTA PHARMACEUTICALS CORP


20-Mar-2014

Change in Directors or Principal Officers, Other Events, Financial Sta


ITEM 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) As previously disclosed, on March 3, 2014, Safi R. Bahcall, Ph.D. notified the Board of Directors of Synta Pharmaceuticals Corp. ("Synta" or the "Company") of his resignation as the President and Chief Executive Officer and as a member of the Board of Directors (the "Board") of Synta.

In connection with Dr. Bahcall's resignation, Synta entered into a Separation Agreement with Dr. Bahcall on March 20, 2014. Pursuant to the terms and conditions of the Separation Agreement, Dr. Bahcall will receive the following:

          Accelerated vesting of all of his unvested stock option awards;



          Extension of the exercise period of all his stock option awards until
the earlier of June 30, 2016 or the expiration date of any applicable stock
option; and

Twenty-four months of his current annual base salary, made in equal installments pursuant to Synta's normal payroll practices over the next twenty-four months.

Dr. Bahcall's right to receive the foregoing is subject to, among other obligations, his agreement to cooperate fully with Synta relating to any previous employment matters until September 3, 2014, his execution of a release of claims against the Company, and his agreement that the confidential, intellectual property and non-solicitation provisions, as well as certain non-competition provisions, set forth in his letter agreement with Synta, dated April 18, 2005, will continue to apply in accordance with their terms.

The foregoing is a summary description of the terms and conditions of the Separation Agreement and is qualified in its entirety by reference to the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Additionally, on March 18, 2014, based upon the recommendation of the Compensation Committee, Synta's Board approved an amendment to its non-employee director compensation policy (the "Amendment"), effective immediately, to establish the compensation of the newly formed Executive Committee, which is overseeing the Company's leadership transition. Pursuant to the Amendment, each member of the Executive Committee is entitled to receive a quarterly retainer of $3,000, prorated for partial quarters and payable in arrears. The Company intends to file a copy of the Amended and Restated Director Compensation Policy, which will incorporate the Amendment, in connection with its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.



ITEM 8.01 Other Events.

On March 20, 2014, Synta issued a press release announcing interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, administered as monotherapy for the treatment of metastatic breast cancer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.



ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number                                   Description

10.1         Separation Agreement between the Company and Dr. Bahcall, dated
             March 19, 2014.
99.1         Press Release, dated March 20, 2014


  Add SNTA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SNTA - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.